[1]Locationinpatent:schemeortableCurran,KevinJ.;Verheijen,JeroenC.;Kaplan,Joshua;Richard,DavidJ.;Toral-Barza,Lourdes;Hollander,Irwin;Lucas,Judy;Ayral-Kaloustian,Semiramis;Yu,Ker;Zask,Arie[BioorganicandMedicinalChemistryLetters,2010,vol.20,#4,p.1440-1444]
[1]Locationinpatent:schemeortableCurran,KevinJ.;Verheijen,JeroenC.;Kaplan,Joshua;Richard,DavidJ.;Toral-Barza,Lourdes;Hollander,Irwin;Lucas,Judy;Ayral-Kaloustian,Semiramis;Yu,Ker;Zask,Arie[BioorganicandMedicinalChemistryLetters,2010,vol.20,#4,p.1440-1444]
Title: Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor.
Journal: Methods in molecular biology (Clifton, N.J.) 20120101
Title: Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Journal: Journal of medicinal chemistry 20110310
Title: Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.
Journal: Bioorganic & medicinal chemistry letters 20100215
Title: Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Journal: Cancer research 20100115
Title: Yu K, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.Cancer Res. 2010 Jan 15;70(2):621-631.